Marijuana Reclassification: 2025 Outlook

The Trump administration is currently reviewing the potential reclassification of cannabis from Schedule I to Schedule III under federal law, a move that could significantly impact the cannabis industry and medical access. A decision is anticipated by the end of 2025.

Story Highlights

  • The Trump administration is actively reviewing marijuana reclassification from Schedule I to Schedule III.
  • A decision is expected by year-end 2025.
  • White House officials have indicated the reform is viewed as “good politics” ahead of the 2026 midterms.
  • Cannabis industry leaders have engaged with the administration, advocating for regulatory relief and banking access.
  • Rescheduling would likely ease research restrictions and expand medical access while maintaining federal oversight.
  • This shift represents a change from the administration’s previous stance, reflecting evolving public attitudes and state-level legalization.

Administration Continues Biden-Era Review with Political Considerations

The Trump administration inherited the marijuana rescheduling process from the Biden White House in January 2025. President Trump has indicated a commitment to making a final determination. Deputy Chief of Staff for Policy Stephen Miller is overseeing the review. In August, President Trump confirmed his team was examining the issue and promised a decision within weeks. White House officials have since acknowledged the potential electoral benefits of marijuana reform in the context of the 2026 midterm races.

Industry Advocacy and White House Engagement

Cannabis industry executives met with President Trump at an August fundraiser in New Jersey. Industry leaders, including Trulieve CEO Kim Rivers, advocated for rescheduling. They argue that the current federal Schedule I classification, which designates cannabis as having no accepted medical use and high abuse potential, creates significant obstacles for research, banking services, and interstate commerce. While 45 states have legalized marijuana in various forms, federal prohibition impacts businesses, forcing many to operate on a cash-only basis and hindering scientific studies into therapeutic applications. 

Potential Economic Benefits and Public Health Concerns

Reclassifying marijuana to Schedule III would immediately ease research restrictions, potentially allowing for more comprehensive studies on its medical benefits and risks. This could lead to the development of new therapies in the pharmaceutical and wellness sectors. Cannabis businesses could gain access to traditional banking systems and potentially qualify for tax deductions currently unavailable under federal law. Economic forecasts suggest increased investment and job creation across the cannabis supply chain. However, public health analysts have expressed concerns that loosening federal restrictions could normalize cannabis use and increase youth access, citing data on accidental ingestion and impaired driving risks. Critics suggest that the administration’s political motivations may be influencing these policy discussions, particularly given the increased potency of modern cannabis products.

Policy Shift Aligns with Evolving Conservative Views

President Trump’s current stance on marijuana marks a notable shift from his first term, during which he privately expressed concerns about its effects. In 2018, his administration, under Attorney General Jeff Sessions, rescinded Obama-era guidance that had de-prioritized federal enforcement in states with legal cannabis markets. The current deliberations reflect a broader pragmatic approach within conservative circles, acknowledging the success of state-regulated markets and the growing conflict between federal prohibition and state sovereignty. Advisors like Alex Bruesewitz have publicly supported rescheduling. Internal White House discussions are weighing legal requirements and policy implications alongside the perceived political advantages. The Department of Justice and Drug Enforcement Administration would be responsible for executing any formal reclassification, with President Trump’s decision being the determining factor.

As of mid-October 2025, the timeline for a final determination remains subject to various pressures from industry advocates seeking quick action and cautious staffers recommending thorough review. Any decision made will significantly alter the landscape for cannabis businesses, medical patients, law enforcement, and the ongoing federal-state legal conflicts that have existed since the 1970s. For conservatives who prioritize limited government and state autonomy, marijuana rescheduling presents an opportunity to align federal policy with both public opinion and constitutional principles, potentially ending decades of federal overreach while maintaining appropriate regulatory oversight. The administration’s willingness to embrace this reform before year-end will be a key indicator of its policy direction.

Watch the report: President Trump considers reclassifying marijuana

Sources:

RELATED ARTICLESMORE FROM AUTHOR

Important Updates

© 2026 Royal Patriot. All Rights Reserved.